As of Aug 28
| +0.09 / +1.73%|
The 4 analysts offering 12-month price forecasts for Endocyte Inc have a median target of 12.50, with a high estimate of 21.00 and a low estimate of 9.00. The median estimate represents a +136.74% increase from the last price of 5.28.
The current consensus among 5 polled investment analysts is to Buy stock in Endocyte Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.